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Throughout  human  history  decisions  on  how  to  treat  sick  or  disabled
persons were almost always based on personal experience, and on the
observation  of  individuals  or  small  groups  of  patients.  But,  following
severe  medical  accidents  and  dramatic  cases  of  exploitative  medical
experiments,  increasingly  controlled  and  systematized  forms  of  clinical
research  were  institutionalized  in  regulation  and  law,  and  enforced  by
government agencies (Roman 2014). Since the late 1970s, the standard
way of drug development has occurred through the translation of basic
research  discoveries  from  (1)  the  lab  bench  (basic  research),  to  (2)
experiments in animal models (pre-clinical research), to (3) the testing of a
candidate therapy in the context of human clinical trials (clinical research)
(Woolf 2008). The go-ahead for the leap from preclinical to human subject
research, and subsequently, to routine use and marketization, is given by
national-level drug regulatory agencies; government bodies (such as the
US Food and Drug Administration, or the European Medicines Agency) that
control and oversee the testing and marketization of new drugs through
formalized investigational and review procedures (Eichler et al. 2010).  
Since the results of a single clinical study are rarely considered as reliable
evidence  for  the  efficacy  and  safety  of  a  medical  product,  device  or
therapy,  an  elaborate  system  of  clinical  trials  emerged,  in  which  the
clinical testing of new drugs is divided in four phases (Friedberg, Furberg
and DeMetz 2010). Phase I to III clinical trials test the safety and efficacy
of  a  candidate  therapy  and  are  conducted  in  the  context  of  an
Investigational  New  Drug  Application  (IND)  procedure,  under  the
supervision  of  a  drug  regulatory  agency.  Phase  IV  trials  are
post-marketization trials.  Phase I  trials  are first-in-human trials that are
designed to test a drug’s safety, toxicity and the most optimal dosage.
They follow from systematic preclinical evidence and enroll relatively small
numbers  of  patients  (ibid.).  Phase  II  trials  test  for  the  efficacy  of  a
candidate  therapy.  They  are  conducted  only  once  the  safety  of  a  new
medicinal  product  or device has been successfully proven in a phase I
human trial. In industry-sponsored compound-based drug trials, commonly
between 200 and 600 human subjects are enrolled in phase II trials (ibid.).
However, in stem cell clinical trials the number of patients is usually much
smaller  (Hyun  2013).  The  purpose  of  phase  III  trials  is  to  confirm the
efficacy  of  a  candidate  therapy  in  a  larger  cohort  of  patients.  The
therapeutic  effects  of  a  drug  are,  as  a  rule,  compared  with  existing
standard  treatments,  or  placebo  treatment.  Phase  III  trials,  can  enroll
between 500 and 20.000 patients (Friedberg, Furberg and DeMetz 2010).
But again, in the context of stem cell clinical trials, or rare disease trials,
this number can be smaller. If the safety and efficacy of a new medicinal
medical product or device has been confirmed in phase I to III trials, drug
regulatory authorities are authorized to give the go-ahead for routine use
and marketization of a therapy (ibid.). The therapy is now legally available
in the jurisdiction in which it has been licensed and approved. Phase IV
trials are post-marketization studies. These trials evaluate the long-term
Copyright © 2013 Centre for Bionetworking. All rights reserved
effects  of  an  approved  drug  and  its  side  effects,  morbidity  and  also
mortality. Such phase IV studies are commonly longitudinal studies that
are conducted over several years (ibid.). 
Since  the  1980s,  phase  II  and  III  trials  are  customarily  conducted  as
double-blinded randomized controlled clinical trial format, which currently
counts as the methodological gold standard (Timmermans and Berg 2004).
Double  blinding,  randomization  and  the  use  of  control  groups,  are
procedures designed to minimize bias, i.e. factors that distort the factual
nature of an observation or event (Friedberg, Furberg and DeMetz 2010). A
control group is, in essence, a comparison group of human study subjects,
who  are  not  treated  with  the  investigational  agent  (i.e.  the  tested
medicinal product or device). These control groups are treated either with
a  placebo  (a  placebo-control  group)  or  a  different  treatment  (active
comparator group) (ibid.). Surgery-based trials make occasionally also use
of  a  control  group  where  patients  undergo  a  sham  surgery
(sham-controlled  trials)  (ibid.).  If  for  ethical  reasons  the  work  with  a
placebo or sham-surgery control group is seen as unacceptable, the study
is  called an “open label  trial”  (i.e.  both patients  and researchers know
which treatment is administered) (Sedgwick 2011). Randomization refers
to the assigning of study participants to the investigational  and control
groups, based on an equal chance procedure. This means, the different
groups of a trial become comparable, because it reduces selection bias,
and ensures  that  biological  covariates  in  patients,  that  may  affect  the
treatment  outcome,  are  equally  distributed  between  treatment  groups
(Friedberg, Furberg and DeMetz 2010). The concept of blinding refers to a
procedure that keeps patients, trial investigators and participant assessors
(the persons who collect the data) unaware of whether patients are part of
an intervention or a control group, so that the behavior of these groups
(and in particular the response of patients) will  not be affected by this
knowledge (ibid.). 
Clinical trials with stem cells
Clinical stem cell trials are based on the same methodological procedures,
as  other  forms of  drug  trials  (Rosen  2006).  There  are,  however,  some
central  differences  to  clinical  trials  that  test  small-molecule  and
compound-based drug products. 
A  first  difference  is  that  the majority  of  stem cell  trials  are  conducted
either as academic (i.e. investigator-initiated) clinical trials, or as clinical
trials  where  small-to-mid  size  biotech  companies  act  as  sponsor.
Large-scale  pharmaceutical  companies  have  so  far  only  invested  in
preclinical research with stem cells, and industry-sponsored trials have not
yet been launched (Ichim, Riordan and Stroncek 2011).
A second difference is that stem cell trials usually make use of significantly
smaller numbers of patients. Phase I trials do often include only between
10  and  40  patients.  Phase  II  trials  may  enroll  between  20  and  100
patients, and phase III trials between 120 and 500 patients. Reasons are
the high costs of stem cell trials, the difficulty to recruit sufficient numbers
of patients and the fact that many of the treatments that are treated with
stem cells are relatively rare diseases, or orphan diseases (Hyun 2013).
Copyright © 2013 Centre for Bionetworking. All rights reserved
A third difference relates to the specific biological characteristics of stem
cells, which pose a number of risks and practical challenges to their use in
clinical trials (ibid.). The most important of these features are: 
(1)Heterogenicity / undesired differentiation: The ability of stem
cells  to  differentiate  in  a  host  environment  in  undesirable  ways,
which may cause injected cells to differentiate into teratoma and
other tumorous cells (Hassan and El-Sheemy 2004).   
(2)Mechanisms of action and migration: The mechanism of action
of  stem  cells  that  unfold  upon  injection  in  a  human  host
environment, are frequently still unknown. Not only is there the risk
of  dysfunctional  differentiation,  but  there  is  also  the  risk  of  cell
migration into areas of the human body, where injected cells could
cause more harm than good (Bianco et al. 2013).  
(3)Microbiological  contamination: micro-biological  interaction
processes  of  stem  cells  in  lab  and  hospital  environments  are
complex, and form a potential source of pollution, that may affect
the therapeutic efficacy and potency of stem cells, and result in the
transmission of viruses or pollutants that may cause severe adverse
effects  in  patients.  Cell  cultivation  and  manufacturing  of  clinical
grade  stem  cells  for  transplantation  requires,  therefore,  highly
skilled staff and first good manufacturing practices (GMP) approved
lab  facilities  in  the  both,  manufacturing  sites  and  clinics.  These
factors  form  a  significant  cost  factor  for  clinical  trials  and
subsequent routine applications (Cobo et al. 2007). 
(4)Fragility: the  successful  survival  of  stem  cells  requires  highly
controlled conditions, and a large numbers of transplanted cells die
after injection. From a perspective of production and transportation
stem cells are problematic, because they have a short shelf life, and
even short-term variation in environment conditions may decrease
the viability and biological characteristics of stem cells, which will
influence  their  behavior  and  efficacy  upon  therapeutic  injection
(Franklin and Kaftantzi 2008). 
(5)Donor variability: Donor-to-donor variability is a further challenge
for stem cell clinical trials. It causes different biological responses in
patients, which may result not only in strong variation with regard
to treatment efficacy, but also in different degrees of HLA rejection,
and related symptoms (Siddappa et al. 2007).
(6)Risks  related  to  surgery: Since  many  stem  cell  treatments
involve  surgery  based  injection  procedures,  the  full  range  of
surgery-related medical risks apply to these stem cell trials. These
risks are: bleeding, microbial contamination, meningitis, and in trials
for neuro-surgical disorders such as stroke or spinal cord injury, also
the  loss  of  cognitive,  sensory  and  motor  function  (Montgomery
2010; Raore 2011). 
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